Cardior Pharmaceuticals GmbH
3 clinical trials · Sponsor
◉ Watch Cardior Pharmaceuticals GmbH
| Record | Firm | Date |
|---|---|---|
| Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy (NCT05953831) | Cardior Pharmaceuticals GmbH | 2024-04-30 |
| Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction (NCT05350969) | Cardior Pharmaceuticals GmbH | 2022-07-07 |
| Clinical Study to Assess Safety, PK and PD Parameters of CDR132L (NCT04045405) | Cardior Pharmaceuticals GmbH | 2019-06-21 |
Track Cardior Pharmaceuticals GmbH automatically
Every clearance here is in the API, with alerts when new ones post.